• Home
  • Study Details
Open

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

The goal of this study is to learn more about what happens when cancer drugs that target specific changes in a tumor's DNA are used to treat tumors that have those DNA changes. We call the use of these types of drugs targeted therapy. A targeted therapy delivers a treatment that is aimed at a specific molecular feature of the cancer cell. The cancer cell being targeted contains a change in the DNA that results in the production of abnormal proteins. These proteins let the cancer cells grow uncontrollably or prevent the body from eliminating the cancer cells. The targeted therapy prevents the abnormal proteins from stimulating the growth of the cancer.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Visit Availability

  • Standard business hours (M-F, 8-5)
  • Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

You will be asked to attend office visits during the course of the study. During visits, you will be asked about your medical history and current medications. Assessments will include physical exams and laboratory tests.

Incentives

Total length of participation:
At least 2 months or until disease progression

Looking for Specific Volunteers

Able to participate:

  • You have advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma
  • Your overall health is stable enough to tolerate treatment
  • You have had genetic testing on your cancer that revealed a mutation targeted by one of the TAPUR trial drugs

Not eligible if:

  • You have has previous treatment of the selected study drug
  • You are receiving any other anti cancer therapy
  • You have a primary brain tumor
  • You have pre-existing cardiac conditions
  • You've had a stroke or heart attack within the last 4 months

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Shetal Patel
Medicine- Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Phase 1 Trials (all cancers))

IRB Number

21-0841

ClinicalTrials.gov

NCT02693535

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research